Managing the case was challenging due to the suboptimal response of dyslipidemia to the various combinations of medication. Genetic testing revealed a rare mutation in the LPL gene, causing familial combined hyperlipidemia (FCH) with an unusual association of lipodystrophy. This evidence concerns the gene LPL and metabolic syndrome.